NCT01355562撤回2 期
Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 4
- 主要终点
- Response rate
研究概览
简要总结
The current study will test single agent IL-2 in stage IV melanoma and kidney cancer.
详细描述
The current study will test single agent IL-2 given daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting in stage IV melanoma and kidney cancer to attempt to determine the response rate, how long the responses last, and median survival of this regimen in these two diseases. Responding patients and those with absence of disease progression may receive additional cycles of therapy every 3 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a histologic diagnosis of metastatic kidney cancer or malignant melanoma Patients may be either newly diagnosed with metastatic disease or may have received prior treatment for metastatic kidney cancer.
- •Patients must have measurable disease on physical exam or radiologic studies.
- •ECOG performance status of 0 or 1 and estimated survival of at least 3 months.
- •White blood count of > 3500/mm3, platelet count > 100,000/mm3, hemoglobin > 9.0 gm/dl; bilirubin, ALT, AST < 2 x upper limit of normal; serum creatinine < 2.0 mg/dl.
- •Patients must undergo a low-level cardiac stress test (or similar cardiac evaluation such as dobutamine stress echocardiogram or radionuclide-based stress test) for possible atherosclerotic heart disease. Patients with a positive stress test would be excluded from this trial.
- •Patients with elevated temperatures > 100.5 F must have sources of occult infection excluded.
- •Patients must be felt to have recovered from effects of prior therapy, such as > 2 weeks after prior chemotherapy.
排除标准
- •Medical illness requiring corticosteroids or other immunosuppressive agents (such as cyclosporin or methotrexate).
- •Autoimmune disease such as inflammatory arthritis, which could be exacerbated by immune-based therapy.
- •Prior history of psychiatric disorder, which could be exacerbated by interleukin-
- •Lactation or pregnancy.
- •Evidence of significant cardiovascular disease including history of recent (< 6 months prior) myocardial infarction, congestive heart failure, primary cardiac arrhythmias (not due to electrolyte disorder or drug toxicity, for example) beyond occasional PVC's, angina, positive low-level stress test, or cerebrovascular accident.
- •Current brain metastasis.
结局指标
主要结局
Response rate
时间窗: 9 weeks
次要结局
- how long the tumor shrinkage lasts(9 weeks)
研究者
Chien-Shing Chen
M.D., Ph.D.
Loma Linda University
研究点 (4)
Loading locations...
相似试验
终止
2 期
TIL Therapy in Metastatic Melanoma and IL2 Dose AssessmentMetastatic MelanomaNCT01995344The Christie NHS Foundation Trust2
已完成
1 期
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune SystemsHIV InfectionsNCT00006066National Institute of Allergy and Infectious Diseases (NIAID)92
已完成
1 期
Interleukin-2 in Treating Patients With Mycosis FungoidesLymphomaNCT00002687University of Washington30
终止
2 期
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCRefractory Metastatic Colorectal CancerpMMRMSSNCT05733611Replimune Inc.5
Unknown
2 期
The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric CancerGastric Cancer, MetastaticNCT02976142Moscow Clinical Scientific Center150